MBX: MBX Biosciences, Inc.
Performance
MBX +111.42%
Watchlist
Select an item
Summary
MBX at a glance
MBX returned +111.42% over the past year. Its worst drop in that year was -37.60%, smaller than 42% of stocks on Redstone, and its Sharpe ratio of 1.30 beats 87% of stocks on Redstone. It pays no dividends.
Current Drawdown
-23.54%
Rolling Volatility
65.49%
Actions
Metrics
Risk Indicators
Alpha88.34%
Beta1.22x
Sharpe1.30
Sortino2.23
Omega1.25
Calmar2.96
Martin5.27
Profile
About MBX
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $2.6B
- Listed
- Sep 2024
- Employees
- 63
- Headquarters
- Carmel, IN
- Website
- mbxbio.com
Comparisons